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Abstract
Background: Routinely collected electronic health records (EHRs) have the potential to enhance randomised
controlled trials (RCTs) by facilitating recruitment and follow-up. Despite this, current EHR use is minimal in UK RCTs,
in part due to ongoing concerns about the utility (reliability, completeness, accuracy) and accessibility of the data.
The aim of this manuscript is to document the process, timelines and challenges of the application process to help
improve the service both for the applicants and data holders.
Methods: This is a qualitative paper providing a descriptive narrative from one UK clinical trials unit (MRC CTU at
UCL) on the experience of two trial teams’ application process to access data from three large English national
datasets: National Cancer Registration and Analysis Service (NCRAS), National Institute for Cardiovascular Outcomes
Research (NICOR) and NHS Digital to establish themes for discussion. The underpinning reason for applying for the
data was to compare EHRs with data collected through case report forms in two RCTs, Add-Aspirin (ISRCTN
74358648) and PATCH (ISRCTN 70406718).
Results: The Add-Aspirin trial, which had a pre-planned embedded sub-study to assess EHR, received data from
NCRAS 13 months after the first application. In the PATCH trial, the decision to request data was made whilst the
trial was recruiting. The study received data after 8 months from NICOR and 15 months for NHS Digital following
final application submission. This concluded in May 2020. Prior to application submission, significant time and effort
was needed particularly in relation to the PATCH trial where negotiations over consent and data linkage took many
years.
Conclusions: Our experience demonstrates that data access can be a prolonged and complex process. This is
compounded if multiple data sources are required for the same project. This needs to be factored in when
planning to use EHR within RCTs and is best considered prior to conception of the trial. Data holders and
researchers are endeavouring to simplify and streamline the application process so that the potential of EHR can be
realised for clinical trials.
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Background
Routinely collected electronic health records (EHRs)
have been identified as an important innovation in the
conduct of randomised clinical trials (RCTs) [1]. EHRs
could improve the efficiency and cost of trials by pos-
sibly enhancing recruitment, more complete data sets
and minimal loss to follow-up [2, 3]. For example, the
TASTE trial (ISRCTN16716833), using the Swedish
angiography and angioplasty registry, is one of several
trials demonstrating the utility of registry-held EHRs to
recruit and follow up participants. This study was able
to recruit 82% of eligible patients from the registry and
obtained complete follow-up data in a trial of 7244 pa-
tients [4]. They also demonstrated meaningfully lower
costs for managing the study with a cost per participant
in the order of ~$50 compared to costs for a conven-
tional RCT which may be in excess of $1000 per partici-
pant [4, 5].
EHRs are often collected by centralised registries and
audits (national or regional) for purposes other than
clinical research to gather detailed information on spe-
cific diseases, treatments or populations. However, there
are concerns, depending on the source, that data col-
lected in this way may not be of appropriate detail or
quality for use in clinical trials [6]. Access to EHRs by
researchers usually requires a formal application to the
data holder where specific criteria must be evidenced in-
cluding compliance with information governance (IG)
regulations and a clear purpose and legal basis for the
data access.
One potential concern for clinical trialists is that the ap-
plication process will be complex and lengthy and that the
data will not be obtained in a timely manner [7]. There
have been reports that RCTs were unable to publish trial
results due to data access [8]. One example is the EPOCH
trial (ISRCTN80682973), where the research team were
unable to procure mortality from Welsh data following
hospital admissions. As a result, the researchers had to
change their planned primary analysis to make sure their
publication was not delayed significantly [9].
The aim of this article is to share and reflect upon our
experience at the MRC Clinical Trials Unit at UCL
(hereafter ‘MRC CTU’) in applying to three national
holders of EHR datasets in the UK for data relating to
two ongoing RCTs. The intention is to highlight some of
the hurdles in obtaining data and discuss possible solu-
tions. The overarching aim is to assist future applicants
and help data providers, who are commonly trying to
improve their processes and address these issues in a
way that is mutually beneficial.
Methods
This is a qualitative study based on recent experience of
the teams at an accredited clinical trials unit (MRC
CTU) in applying for and accessing routine datasets in
England (for two separate trials). The data access appli-
cations are linked by one main applicant as part of their
clinical methodology research and use a descriptive nar-
rative from documented exchanges between the data
holder and applicant to establish themes for discussion.
These were chosen as they cover recent access to some
of the main datasets likely to be used by clinical trialists
with a range of common clinical outcomes. The MRC
CTU sought English EHR data for the Add-Aspirin
(ISRCTN 74358648) and PATCH (ISRCTN 70406718)
trials.
Add-Aspirin aims to assess whether daily aspirin use
after treatment for an early-stage cancer can prevent re-
currence and improve survival [10]. It will recruit 11,000
participants in the UK, Republic of Ireland and India; re-
cruitment began in October 2015 and is ongoing. The
Add-Aspirin protocol includes a methodological sub-
study designed to assess the feasibility of applying for
and using EHRs from the National Cancer Registration
and Analysis Service (NCRAS) [11] to assist in the long-
term follow-up of participants after completion of trial
treatment.
PATCH is a randomised trial of approximately 2500
participants with prostate cancer in the UK. It is asses-
sing the efficacy and safety of a novel therapy transder-
mal oestradiol patches against standard hormone
therapy [12]. Transdermal patches may have a better
side-effect profile compared with standard treatment
but there was a prior concern about increased cardio-
vascular toxicity based on trials of oral oestrogens in
the 1970s. PATCH therefore had enhanced monitoring
of cardiovascular outcomes, gathering all available in-
formation about each event with an additional clinical
review [12]. After the trial started, a methodology sub-
study was initiated to compare serious adverse cardio-
vascular events reported by research staff at participat-
ing sites through trial-specific data collection forms
with those routinely collected from, and reported in,
audits held by the National Institute for Cardiovascular
Outcomes Research (NICOR) and Hospital Episodes
Statistics (HES) held by NHS Digital. Concordance be-
tween the three datasets would support the premise
that routinely collected data could supplement or re-
place long-term cardiotoxicity data in this trial and
other future RCTs.
The routine data to be accessed for these two projects
are held and collated by three different organisations
with their own individual processes to allow data access.
Although the organisations are all within the auspices of
the English National Health Service, each has evolved in
recent years. This, along with revisions to the legal
framework for IG, means that the process of data access
has also evolved.
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National Cancer Registration and Analysis Service (NCRA
S)
In 2016, NCRAS was formed from the merger of the Na-
tional Cancer Intelligence Network (NCIN) and National
Disease Registration (NDR) within Public Health Eng-
land [13]. In England, NCRAS manages the collection of
data relating to cancer. The aim is to monitor cancer in-
cidence, improve care and clinical outcomes, aid re-
search and support genetic counselling [11]. NCRAS
hold several different datasets covering cancer registra-
tion and cancer treatments (systemic therapy and radio-
therapy). They can also link these datasets to others held
by NHS Digital or the Office for National Statistics
(ONS), such as mortality data and HES, via NHS num-
ber or other personal identifiers.
To gain access to this data for research, an applica-
tion must be submitted to the Office for Data Release
(ODR) [14]. The ODR application process is outlined
in Fig. 1 [14].
NHS Digital
NHS Digital has been the custodian of HES since 2016.
Prior to this, it operated under the Health and Social
Care Information Centre (HSC-IC) from 2005 [15]. NHS
Digital collects, processes and provides access to many
EHR datasets and is continually seeking to supplement
this data with other datasets from various care settings.
HES is primarily a resource for reimbursement of hos-
pital activity and holds patient-level information on
more than 500 variables ranging from diagnosis, proce-
dures, admission dates, demographics of the patients
and healthcare provider [16]. NHS Digital has a large
number of organisations requesting access to their data
with most coming from local authorities and Clinical
Commissioning Groups [8]; access is provided by
application to the Data Access Request Service (DARS)
[17]. The Independent Group Advising on the Release of
Data (IGARD) gives an independent final review that
aims to improve transparency, accountability, quality
and consistency of the application process. IGARD cur-
rently meets weekly to make sure that applications are
reviewed in a timely fashion. The application process
continues to change with attempts to improve its ser-
vice; the current process is outlined in Fig. 2 [17].
National Institute for Cardiovascular Outcomes Research
(NICOR)
NICOR collects routine EHR data and produces analyses
to enable hospitals and healthcare improvement bodies
to monitor and improve the care and outcomes of pa-
tients with cardiovascular disease. It manages six na-
tional clinical audits and a number of new health
technology registries [18]. NICOR is regulated and
contracted by the Health Quality Improvement Partner-
ship (HQIP). NICOR was originally hosted by UCL but
moved to Barts Health NHS Trust in 2017. The two au-
dits that were identified as potentially relevant to the
PATCH trial were the National Heart Failure Audit
(NHFA) and the Myocardial Ischaemia National Audit
Project (MINAP). The application process to obtain data
from NICOR is shown in Fig. 3 [18]. Historically, far
fewer researchers have used this source compared to
NHS Digital and NCRAS [8].
Findings
Add-Aspirin
The Add-Aspirin trial was conceived with the recogni-
tion that participants will require follow-up for at least
10 years [10]. This length of follow-up is required to as-
sess the overall risk: benefit of regular aspirin use on the
Fig. 1 Flow diagram of data access via the Office for Data Release (ODR) for National Cancer Registration and Analysis Service (NCRAS) data,
adapted from Public Health England (PHE) [14]
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trial participants’ health. From the design stage of the
trial, like for many trials [19], there was an intention to
access data using routinely collected EHRs. When the
trial was initially conceived in 2012, the Add-Aspirin
trial team met with individuals from NCIN, the prede-
cessor of NCRAS, to assess the feasibility of accessing
data and also to ensure that an appropriate budget for
this activity was incorporated into funding applications
(Fig. 4). The protocol, patient information sheets and
consent forms were designed to reflect the potential use
of routinely collected healthcare data.
In 2017, after 2 years of recruitment and follow-up,
there was a conversation with ODR to confirm the cost
and current application process. In 2018, there was suffi-
cient data to initiate the pre-defined methodology sub-
study. A pre-application meeting with an ODR senior
Fig. 2 Flow diagram of the Data Access Request Service (DARS) for NHS Digital data, adapted from NHS Digital [17]. IGARD, Independent Group
Advising on the Release of Data
Fig. 3 Data access request for access to National Institute for Cardiovascular Outcomes Research (NICOR) data adapted from [18]. HQIP, Health
Quality Improvement Partnership; NCAP, National Cardiac Audit Programme
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manager established the documentation that was needed
going forward.
Following the implementation of the General Data
Protection Regulation (GDPR) in the UK (2018), trans-
parency of how exactly participant data would be used
became a legal requirement. The previously agreed con-
sent forms and patient information sheets did not meet
the 2018 requirements of GDPR. The solution was for a
privacy notice to be drafted and made publicly accessible
on the trial’s website. The trial’s IG documentation also
needed updating to ensure information security assur-
ances (via the Data Security and Protection Toolkit)
were in place within UCL.
Following submission of the data application (Decem-
ber 2018), ODR sent back revisions (January 2019) and
confirmed the transparency statement (February 2019).
For the application to proceed, an analyst needed to be
allocated to check the defined data requirements. In
April 2019, NCRAS unfortunately unassigned the analyst
allocated to Add-Aspirin onto work on a project consid-
ered more critical. There was a meeting in May 2019,
once further analytical support had been deployed, to
discuss the data field requests. The new analysts sug-
gested that a number of data fields should be expanded
to give the best chance of capturing cancer recurrence
as this is not, at present, collected sufficiently well within
any single EHR dataset. They acknowledged at that time
that algorithms were needed to identify data patterns in-
dicative of tumour recurrence. ODR wanted to ensure
that no unnecessary data from HES was provided for
each participant. The MRC CTU therefore provided sur-
gical/procedure codes (using Office of Population Cen-
suses and Surveys (OPCS) definitions) and diagnosis
codes (ICD-10 codes) to NCRAS to focus and limit the
data extraction. In June 2019, it was agreed with ODR
and NCRAS that, as this was a methodological project
reviewing ways to gather trial outcomes in registry data,
all HES data for these patients could be given to the
MRC CTU.
The application then underwent an ODR internal
moderation review, and a month later, a data sharing
agreement (DSA) was sent from ODR to MRC CTU. Be-
tween August and October 2019, there were ongoing
discussions between the MRC CTU contracts depart-
ment and the ODR. The final DSA was signed on behalf
of MRC CTU on 16 October 2019 and fully executed by
ODR on 15 November 2019. A further new analyst was
then assigned to the project who re-reviewed the data
request. This new analyst advised an update to the data
censor dates, since more up-to-date data was now avail-
able from NCRAS. The updated data request was sent
back to ODR for re-signing. The DSA was re-signed and
the MRC CTU checked the current consent status of pa-
tients before sending participants identifiable data to
NCRAS on 23 December 2019. The one-off data extracts
were successfully received at the MRC CTU on 06 Feb-
ruary 2020. This 6-week interval before data receipt was
due to NCRAS rewriting their standard filters to provide
C44 (non-melanoma skin cancer) — a code that is not
usually supplied but needed for this trial. In total, this
application, excluding the planning and preparatory
work, took approximately 13 months from submission
of the application to receiving the data.
PATCH
The PATCH trial opened to recruitment in 2006 as a
phase II feasibility trial, developing into a phase III RCT
in 2013. The trial was not initiated with the use of EHR
in mind but there was a statement included in the
Fig. 4 Flow diagram of the Add-Aspirin National Cancer Registration and Analysis Service (NCRAS) application. (Please note that timeline is not
proportional) REC approval for Add-Aspirin March 2014. Recruitment opened in October 2015 and is ongoing. CTU, clinical trials unit; DSA, data
sharing agreement; NCIN, National Cancer Intelligence Network; ODR, Office for Data Release; REC, Research Ethics Committee
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consent form to potentially allow information to be
sought from the national registries in the future:
I agree that my details including my full name can
be given to the MRC such that long-term follow-up
information from the NHS Information Centre and
the NHS Central Register or any applicable NHS in-
formation system.
With the assumption of valid consent for the use of
EHR data, a methodological sub-study was devised to
triangulate cardiovascular event data between HES,
NICOR and trial data. There was an initial scoping of
the project in 2014 with NICOR and HSC-IC advising
data linkage before comparison at the MRC CTU (Fig.
5). During the initial conversations with NICOR and
HSC-IC, the organisations stated that the consent state-
ment was insufficient to acquire linked data from these
two sources without first gaining approval from the
Confidentiality Advisory Group (CAG). In 2016, the
process to submit a CAG application was started. Several
months of delays followed due to difficulty in acquiring
the appropriate IG documentation for PATCH. CAG re-
quire detailed IG documentation for both the trial but
also in this case from NICOR and NHS Digital (formerly
HSC-IC until 2016). There were difficulties in identifying
the appropriate person for this information within NHS
Digital, taking most of 2016 to achieve (note: at this
time, case officers were not assigned until after the ap-
plication was formally submitted). During 2016, an alter-
native method of data access was explored via NCRAS,
but as no cancer data was being sought, this option was
deemed unviable. Consequently, in 2017, the project was
put on hold.
In October 2018, the MRC CTU re-engaged with
NICOR (which had moved to Barts Health NHS Trust
following a European Union tender process) and NHS
Digital. There were additional complexities for obtaining
CAG approval as the PATCH trial at the time was in the
process of changing sponsor and therefore the CAG ap-
plication could not be approved.
As the explicit wording on the consent form was the
main issue preventing access to the data, the MRC CTU
asked the MRC Regulatory Support Centre for further
guidance. They felt that the consent wording was suffi-
cient. NICOR subsequently agreed that, if their data was
not sent to NHS Digital for linkage, then CAG approval
was not necessary. Therefore a further application was
submitted and sent to NICOR for review (Fig. 3).
NICOR’s review was completed in May 2019. The appli-
cation was then submitted to HQIP by NICOR. The ap-
plication was reviewed in June and amendments were
Fig. 5 Flow diagram of the PATCH joint application to NHS Digital and National Institute for Cardiovascular Outcomes Research (NICOR) and
subsequently handled as separate applications in 2018. (Please note that timeline is not proportional) REC approval for PATCH November 2005.
Recruitment opened in April 2006 and is ongoing. CAG, Confidentiality Advisory Group; DAO, data approvals officer; DARS, Data Access Request
Service; HQIP, Health Quality Improvement Partnership; HSC-IC, Health and Social Care Information Centre; IGARD, Independent Group Advising
on the Release of Data; REC, Research Ethics Committee
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returned to MRC CTU. HQIP issued a signed DSA on
19 July 2019, and a NICOR analyst was assigned. The
analyst continued discussions with the MRC CTU on
data extraction, and a one-off data extract was received
at the MRC CTU on 17 October 2019.
As with NICOR, NHS Digital was re-engaged in Octo-
ber 2018, and it took several weeks to allow access to
the DARS online system due to technical difficulties
with the DARS system (Fig. 5). A new DARS application
was submitted in February 2019, but this was initially
rejected due to issues around consent and sponsorship
and not meeting the DARS checklist criteria. After a
phone call to DARS and changes to the application by
the MRC CTU, it was accepted and a case officer allo-
cated. The case officer reviewed and made extensive
comments with required changes. A privacy notice was
created for the project and circulated to participants
once it was ethically approved. NHS Digital then advised
that the application could not proceed until the NICOR
DSA was signed, sponsorship clarified and the new
protocol for the sub-study had been ethically approved.
Sponsorship was not resolved until September 2019,
and at that point, the MRC CTU re-engaged with NHS
Digital. On receipt of the revised application, NHS
Digital returned it to the DARS triage service and a new
case officer was allocated. Over the next few months, the
case officer made amendments to the application and
sent it internally to the data approvals officer (DAO).
The DAO asked for further changes to the application
to clarify certain points and was submitted to IGARD in
December 2019 for final review. IGARD approved the
application in January subject to one last data specifica-
tion amendment. The DSA was signed on behalf of the
MRC CTU in February 2020, and the MRC CTU
uploaded identifiable data to NHS Digital in March. The
NHS Digital production team made data available in
May and data was received at the MRC CTU on 21 May
2020. When all efforts are taken into consideration, it
has taken several years to obtain data from both of these
providers. However, from the most recent effort, data
was received approximately 8 and 15 months after sub-
mission of formal applications to NICOR and NHS
Digital respectively.
Discussion
This article describes the MRC CTU’s experience of
attempting to access EHR data from three English na-
tional data holders (NCRAS, NICOR and NHS Digital)
for two large trials with a view to identifying shareable
lessons. These data access applications were chosen as
they were both for methodological studies embedded
within RCTs looking at the appropriateness of EHR data
to be used in trial follow-up with the important juxta-
position of where data access is planned versus being a
later addition. The aim was to improve the knowledge
and experience of gaining access to these datasets and to
assess the accuracy of nationally held EHR data com-
pared to data manually collected as part of conventional
trial-specific follow-up. Our experience was challenging
and took many person hours over 8 to 15 months from
formally submitting an application to receiving the data.
There are limitations to this paper as this is specific to
English national data holders and other countries may
not have the same application issues or comparable
registry data quality. This is also an experience paper
from one clinical trials unit, and the difficulties we had
in acquiring the data may potentially be unique. The na-
ture of the trials, the infrastructure within this specific
trials unit, the introducing of significant data protection
legislation (GDPR; May 2018) during the period that
provide new requirements, and the relative infrequency
of our applications could be factors in the delays en-
countered. The process of applying for data for the
PATCH trial started more than 5 years ago but the most
recent iteration of applications for data started in Octo-
ber 2018. However, this is not a story in isolation and
there have been other publications demonstrating simi-
lar problems [7, 9, 20, 21]. At present, the application
process for each of these datasets is too complicated and
discourages researchers from using this invaluable data.
A recent survey of the cancer research community, con-
ducted by the National Cancer Research Institute, found
that less than half were successful in accessing data from
the national datasets and, when asked what would help
most, the majority answered ‘support through data ac-
cess process’ and ‘improving timelines for the applica-
tion approval’ [22]. The difficulty of accessing this data
may be why so few clinical trials have used national
datasets to enrich or replace data collected via conven-
tional case report forms [8].
From a clinical trialist perspective, several lessons have
been learnt about the process of applying for and obtain-
ing EHR data. Firstly, it is extremely challenging to ac-
quire data for an actively recruiting trial that had not
planned this acquisition in advance. The main issue for
the PATCH trial application was the wording in the trial
protocol, consent forms and patient information sheets
were not initially designed for the sub-study when the
application process was started. Although the wording
followed current recommendations when first written,
information governance procedures and regulations
evolved. In contrast, the Add-Aspirin trial had a good
foundation due to prior preparation work before the ap-
plication process began which meant fewer amendments
were needed due to new data laws. Clinical trials units
need to work closely with registries and data holders to
establish the most efficient methods to obtain and access
EHR data; this could include clear guidance on the
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optimal timing of data requests (such as at trial initi-
ation) and accessible, transparent cost structures to
allow trialists to obtain sufficient funding for repeated
data access through the lifetime of a trial.
Secondly, all clinical trials units need appropriate in-
frastructure to have the high level of data security
needed for storing EHR data, and evidenced through a
completed and endorsed Data Security and Protection
Toolkit. An example includes the formation of ‘Trusted
Research Environments’ which allow a cyber-secure vir-
tual location where identifiable data cannot be removed
and only verified researchers can access depending on
IG training and specified parameters. Such infrastructure
is complicated and costly taking considerable time to set
up and to manage going forward. Once the required in-
frastructure is established, then the data security and IG
controls should be valid for any national dataset. The
connectivity of these datasets is also an issue, with separ-
ate applications having to be completed to several orga-
nisations/countries within the UK which takes a
considerable amount of time and money. One solution
would be a ‘passport’ system for data access to allow an
institution that has demonstrated appropriate data se-
curity and IG controls to fast track the process. Another
solution would be to link more datasets and allow only
one application for both. There are new initiatives on-
going with examples of collaboration such as VICORI
which links between NICOR and NCRAS data [23].
Lastly, the applicant also needs experience in how to
answer the questions in the forms to stand up to the
scrutiny of the data controllers’ checks. These assess-
ments are appropriate but, without prior knowledge, ap-
plications are often rejected due to wording rather than
due to the nature of their request. This could make it
difficult for clinical trials units that only apply occasion-
ally since key knowledge may be lost inducing repetitive
errors again, or the team is unaware of how the process
has changed. This lack of experience can only be helped
by resources provided by the dataset organisations and
more guidance through the application process by expe-
rienced case officers within those organisations.
NHS Digital and NCRAS are continuing to improve
their accessibility through guidelines for the application
process, seminars and videos. NHS Digital has established
a clinical trials service in collaboration with Health Data
Research UK, the University of Oxford, IBM and Micro-
soft [24]. This ‘NHS DigiTrials’ is in its infancy and is ini-
tially concentrating on helping new trials with the
identification of potential participants and follow-up of
participants during and post-trial. As part of this, it is
directing its attention to helping with data access from
EHR for clinical trials by increasing the speed of access
and a wider range of data types available. NICOR are also
striving to streamline their application process internally
and with HQIP to avoid unnecessary delays for appropri-
ate research applications. During the COVID pandemic,
there has also been data sharing and routine linkage for
the first time between NICOR and NHS Digital that has
been used in a number of publications [25].
For routinely collected EHR to be a viable option of pro-
viding data for clinical trials, data access must take no lon-
ger than a few months; otherwise, delays cause difficulty
with funding and the timeliness for reporting key outcomes.
Also, the records within the databases need to be up-to-
date. Some may have a reporting lag of up to a year and
that limits their utility. Also, better coordination and link-
age between the datasets held by separate data controllers
would reduce the burden on the applicants. Health Data
Research UK (HDR UK) is working with key stakeholders
to improve data ‘inclusivity and transparency’ to push the
agenda of utilisation of data for science with relevant orga-
nisations but also with the public as well. This also includes
improving navigation across datasets from different data
controllers, via the Health Data Research Innovation Gate-
way, and bringing together different data controllers under
the UK Health Data Alliance [26]. This is to be consistent
with their bold statement of ‘Our Data, Our Society, Our
Health’ [20]. This will hopefully allow the right data to be
given to the right people in an efficient but transparent way
and provide reassurance to the general public. The accessi-
bility is the first challenge in the use of this data but there is
still concern about how appropriate the data is, given that it
is not designed for clinical trials. Evaluation of the reliabil-
ity, completeness and accuracy of data is needed. The ana-
lysis of the EHR data of the two methodology projects
described above is ongoing and will be the subject of separ-
ate publications which will further inform the discussion
around the utility of EHR in trials.
Conclusion
EHR contains a wealth of information about individual
patient’s health outcomes, which can be useful for clin-
ical trials. Our experience demonstrates that data access
can be a prolonged and complex process. This is com-
pounded by the fact that multiple data sources, some-
times from different data holders, will often be required
for the same project. Improving data access would be
the first step to realise the potential of these datasets.
Based on our experience successfully accessing datasets
from NHS Digital, NCRAS and NICOR, we have identi-
fied pre-planned acquisition of data prior to trial set up
is important for researchers considering the use of EHR
data for their clinical trials to establish appropriate con-
sent, legal purpose and infrastructure to comply with
data security and law. Data holders and researchers are
endeavouring to simplify and streamline the application
process so that the potential of EHR can be realised for
clinical trials.
Macnair et al. Trials          (2021) 22:340 Page 8 of 10
Abbreviations
CAG: Confidentiality Advisory Group of the Health Research Authority (HRA);
CTU: Clinical trial unit; DAO: Data approvals officer; DARS: Data Access
Request Service; DSA: Data sharing agreement; EHR: Electronic health record;
GDPR: General Data Protection Regulation (EU) 2016/679; implemented 25
May 2018; HDR UK: Health Data Research UK; HES: Hospital Episodes
Statistics; HQIP: Health Quality Improvement Partnership; HSC-IC: Health and
Social Care Information Centre; IG: Information governance; IGAR
D: Independent Group Advising on the Release of Data; MINAP: Myocardial
Ischaemia National Audit Project; MRC CTU: Medical Research Council Clinical
Trials Unit at UCL; NCAP: National Cardiac Audit Programme; NCIN: National
Cancer Intelligence Network; NCRAS: National Cancer Registration and
Analysis Service; NDR: National Disease Registration; NHFA: National Heart
Failure Audit; NICOR: National Institute for Cardiovascular Outcomes
Research; ODR: Public Health England (PHE) Office for Data Release;
ONS: Office for National Statistics; OPCS: Office of Population Censuses and
Surveys; Privacy notice: A statement made to a data subject that describes
how the organisation collects, uses, retains and discloses personal
information; also known as a transparency notice; REC: Research Ethics
Committee
Acknowledgements
We acknowledge and are grateful to NHS Digital Research and clinical trials
team and to Mark De Belder, NICOR Operational and Methodology Group
Chair, and Luke Hounsome, PhD, Analytical Programme Manager at NCRAS
for their comments received on the draft manuscript.
Authors’ contributions
AM conceived the manuscript and led the writing. REL, SL, JC, TD, MM and
MS wrote critical sections and reviewed and agreed the final version. REL,
DG, FC and MP are clinical and statistical leads for Add-Aspirin and PATCH
trials and reviewed and agreed the final version of the document. The au-
thors read and approved the final manuscript.
Funding
This work was supported by Health Data Research UK; Medical Research
Council MC_UU_12023/24. The Add-Aspirin trial is being jointly funded by
Cancer Research UK (grant number C471 /A15015), The National Institute for
Health Research Health Technology Assessment Programme (project refer-
ence 12/01/38) and the MRC Clinical Trials Unit at UCL (MC_UU_12023/28).
The views expressed are those of the author(s) and not necessarily those of
the NIHR or the Department of Health and Social Care. The PATCH study is
funded by Cancer Research UK, grant number C471/A12443 (trial CRUK/06/
001) and University College London (UCL), is now sponsored by UCL and
was previously sponsored by Imperial College London.
Availability of data and materials
Data sharing is not applicable to this article as no datasets were generated
or analysed during the current study.
Declarations
Ethics approval and consent to participate
Add-Aspirin was approved by the South Central – Oxford C research ethics
committee and is part of the UK National Cancer Research Network (NCRN)





All authors have completed the ICMJE uniform disclosure form at www.
icmje.org/coi_disclosure.pdf and declare no support from any organisation
for the submitted work; however, MS reports grants from Health Data
Research UK, during the conduct of the study; personal fees from Lilly
Oncology; personal fees from Janssen; grants and non-financial support from
Astellas; grants and non-financial support from Clovis Oncology; grants and
non-financial support from Janssen; grants and non-financial support from
Novartis; grants and non-financial support from Pfizer; and grants and non-
financial support from Sanofi-Aventis, outside the submitted work; FC reports
receipt of research grants for the Add-Aspirin trial from Cancer Research UK
and the National Institute of Health Research, as well as study drug provision
from Bayer Pharmaceuticals. REL reports grants from Cancer Research UK;
grants from UK Medical Research Council, during the conduct of the study;
and personal fees from Aspirin Foundation, outside the submitted work.
Author details
1MRC Clinical Trials Unit at UCL, UCL, London WC1V 6LJ, UK. 2Health Data
Research UK, London, UK. 3NHS Digital, 1 Trevelyan Square, Leeds LS1 6AE,
UK. 4Medical Statistics, London School of Hygiene and Tropical Medicine,
London WC1E 7HT, UK.
Received: 6 October 2020 Accepted: 24 April 2021
References
1. Lauer MS, D’Agostino RB. The randomized registry trial — the next
disruptive technology in clinical research? New Engl J Med. 2013;369(17):
1579–81. https://doi.org/10.1056/NEJMp1310102.
2. Mc Cord KA, Al-Shahi Salman R, Treweek S, Gardner H, Strech D, Whiteley
W, et al. Routinely collected data for randomized trials: promises, barriers,
and implications. Trials. 2018;19(1):29. https://doi.org/10.1186/s13063-017-23
94-5.
3. Appleyard SE, Gilbert DC. Innovative solutions for clinical trial follow-up:
adding value from nationally held UK data. Clin Oncol. 2017;29(12):789–95.
https://doi.org/10.1016/j.clon.2017.10.003.
4. Lagerqvist B, Fröbert O, Olivecrona GK, Gudnason T, Maeng M, Alström P,
et al. Outcomes 1 year after thrombus aspiration for myocardial infarction.
New Engl J Med. 2014;371(12):1111–20. https://doi.org/10.1056/NEJMoa14
05707.
5. Shore BJ, Nasreddine AY, Kocher MS. Overcoming the funding challenge:
the cost of randomized controlled trials in the next decade. JBJS. 2012;
94(Supplement_1):101–6.
6. McCord K, Hemkens L. Using electronic health records for clinical trials:
where do we stand and where can we go? Can Med Assoc J. 2019;191(5):
E128–E33. https://doi.org/10.1503/cmaj.180841.
7. Lugg-Widger F, Angel L, Cannings-John R, Hood K, Hughes K, Moody G,
et al. Challenges in accessing routinely collected data from multiple
providers in the UK for primary studies: managing the morass. Int J Popul
Data Sci. 2018;3(3):1–14.
8. Lensen S, Macnair A, Love SB, Yorke-Edwards V, Noor NM, Martyn M, et al.
Access to routinely collected health data for clinical trials – review of
successful data requests to UK registries. Trials. 2020;21(1):398. https://doi.
org/10.1186/s13063-020-04329-8.
9. Peden CJ, Stephens T, Martin G, Kahan BC, Thomson A, Rivett K, et al.
Effectiveness of a national quality improvement programme to improve
survival after emergency abdominal surgery (EPOCH): a stepped-wedge
cluster-randomised trial. Lancet. 2019;393(10187):2213–21. https://doi.org/1
0.1016/S0140-6736(18)32521-2.
10. Coyle C, Cafferty FH, Rowley S, MacKenzie M, Berkman L, Gupta S, et al.
ADD-ASPIRIN: a phase III, double-blind, placebo controlled, randomised trial
assessing the effects of aspirin on disease recurrence and survival after
primary therapy in common non-metastatic solid tumours. Contemp Clin
Trials. 2016;51:56–64. https://doi.org/10.1016/j.cct.2016.10.004.
11. Public Health England. Guidance National Cancer Registration and Analysis
Service 2020 [Available from: https://www.gov.uk/guidance/national-cancer-
registration-and-analysis-service-ncras. Accessed 19/02/2020.
12. Langley RE, Cafferty FH, Alhasso AA, Rosen SD, Sundaram SK, Freeman SC,
et al. Cardiovascular outcomes in patients with locally advanced and
metastatic prostate cancer treated with luteinising-hormone-releasing-
hormone agonists or transdermal oestrogen: the randomised, phase 2 MRC
PATCH trial (PR09). Lancet Oncol. 2013;14(4):306–16. https://doi.org/10.1016/
S1470-2045(13)70025-1.
13. Public Health England. National Cancer Intelligence Network (NCIN): 30 +
years of cancer intelligence - challenges of technologies of the time
[Available from: http://www.ncin.org.uk/home. Accessed 09/08/2019.
14. Public Health England. Guidance accessing PHE data through the Office for
Data Release 2020 [Available from: https://www.gov.uk/government/publica
tions/accessing-public-health-england-data/about-the-phe-odr-and-a
ccessing-data. Accessed 19/02/2020.
Macnair et al. Trials          (2021) 22:340 Page 9 of 10
15. Gov.uk. HSCIC changing its name to NHS Digital 2016 [Available from:
https://www.gov.uk/government/news/hscic-changing-its-name-to-nhs-
digital. Accessed 19/02/2020.
16. Boyd A. Understanding Hospital Episode Statistics (HES). London, UK:
CLOSER; 2017.
17. NHS Digital. Data Access Request Service (DARS): process 2019 [Available
from: https://digital.nhs.uk/services/data-access-request-service-dars/data-a
ccess-request-service-dars-process. Accessed 20/02/2020.
18. NICOR. NICOR 2020 [Available from: https://www.nicor.org.uk/. Accessed 20/
02/2020.
19. McKay AJ, Jones AP, Gamble CL, et al. Use of routinely collected data in a
UK cohort of publicly funded randomised clinical trials. F1000Research.
2020;9:323.
20. Ford E, Boyd A, Bowles JKF, Havard A, Aldridge RW, Curcin V, et al. Our data,
our society, our health: a vision for inclusive and transparent health data
science in the United Kingdom and beyond. Learning Health Systems. 2019;
3(3):e10191. https://doi.org/10.1002/lrh2.10191.
21. Dattani N, Hardelid P, Davey J, Gilbert R. Accessing electronic administrative
health data for research takes time. Arch Dis Childhood. 2013;98(5):391–2.
https://doi.org/10.1136/archdischild-2013-303730.
22. National Cancer Research Institute. The researchers’ experience when
attempting to access health data for research 2020 [Available from: https://
www.ncri.org.uk/ncri-blog/accessing-health-data-for-research/. Accessed 28/
02/2020.
23. Public Health England. Current analytical partnerships involving the National




24. NHS Digital. NHS DigiTrials 2020 [Available from: https://digital.nhs.uk/
services/nhs-digitrials. Accessed 01/06/2020.
25. Mohamed MO, Gale CP, Kontopantelis E, Doran T, de Belder M, Asaria M,
et al. Sex-differences in mortality rates and underlying conditions for COVID-
19 deaths in England and Wales. Mayo Clinic Proceedings. 2020;95(10):
2110–24. https://doi.org/10.1016/j.mayocp.2020.07.009.
26. Health Data Research UK. Health Data Research Innovation Gateway 2020
[Available from: https://www.healthdatagateway.org/. Accessed 01/06/2020.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Macnair et al. Trials          (2021) 22:340 Page 10 of 10
